77 related articles for article (PubMed ID: 21327931)
1. Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers.
Shimoyama S
Cancer Chemother Pharmacol; 2011 Apr; 67(4):729-39. PubMed ID: 21327931
[TBL] [Abstract][Full Text] [Related]
2. Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.
Ramos FJ; Macarulla T; Capdevila J; Elez E; Tabernero J
Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S52-7. PubMed ID: 19064407
[TBL] [Abstract][Full Text] [Related]
3. Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy.
Hendrickson AW; Haluska P
Curr Opin Investig Drugs; 2009 Oct; 10(10):1032-40. PubMed ID: 19777391
[TBL] [Abstract][Full Text] [Related]
4. Drug development for cancer chemoprevention: focus on molecular targets.
Johnson KA; Brown PH
Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
[TBL] [Abstract][Full Text] [Related]
5. Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapy.
Serrano C; Markman B; Tabernero J
Cancer J; 2010; 16(3):226-34. PubMed ID: 20526101
[TBL] [Abstract][Full Text] [Related]
6. Resistance to epidermal growth factor receptor-targeted therapy.
Morgillo F; Lee HY
Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
[TBL] [Abstract][Full Text] [Related]
7. Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma.
Dempke WC; Heinemann V
Anticancer Res; 2010 Nov; 30(11):4673-7. PubMed ID: 21115922
[TBL] [Abstract][Full Text] [Related]
8. Targeting apoptosis as an approach for gastrointestinal cancer therapy.
Qiao L; Wong BC
Drug Resist Updat; 2009 Jun; 12(3):55-64. PubMed ID: 19278896
[TBL] [Abstract][Full Text] [Related]
9. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours.
Höpfner M; Baradari V; Huether A; Schöfl C; Scherübl H
Endocr Relat Cancer; 2006 Mar; 13(1):135-49. PubMed ID: 16601284
[TBL] [Abstract][Full Text] [Related]
10. Targeting growth factors and angiogenesis; using small molecules in malignancy.
Wanebo HJ; Argiris A; Bergsland E; Agarwala S; Rugo H
Cancer Metastasis Rev; 2006 Jun; 25(2):279-92. PubMed ID: 16770540
[TBL] [Abstract][Full Text] [Related]
11. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era.
Wagner AD; Moehler M
Curr Opin Oncol; 2009 Jul; 21(4):381-5. PubMed ID: 19412098
[TBL] [Abstract][Full Text] [Related]
12. The statins as anticancer agents.
Chan KK; Oza AM; Siu LL
Clin Cancer Res; 2003 Jan; 9(1):10-9. PubMed ID: 12538446
[TBL] [Abstract][Full Text] [Related]
13. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
Feldkamp MM; Lau N; Guha A
Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
[TBL] [Abstract][Full Text] [Related]
14. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway.
Kodach LL; Bleuming SA; Peppelenbosch MP; Hommes DW; van den Brink GR; Hardwick JC
Gastroenterology; 2007 Oct; 133(4):1272-81. PubMed ID: 17919499
[TBL] [Abstract][Full Text] [Related]
15. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
Baselga J; Arteaga CL
J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
[TBL] [Abstract][Full Text] [Related]
16. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor mutations in lung cancer.
Sharma SV; Bell DW; Settleman J; Haber DA
Nat Rev Cancer; 2007 Mar; 7(3):169-81. PubMed ID: 17318210
[TBL] [Abstract][Full Text] [Related]
18. Amplification of epidermal growth factor receptor gene but no evidence of ras mutations in primary human esophageal cancers.
Hollstein MC; Smits AM; Galiana C; Yamasaki H; Bos JL; Mandard A; Partensky C; Montesano R
Cancer Res; 1988 Sep; 48(18):5119-23. PubMed ID: 3044581
[TBL] [Abstract][Full Text] [Related]
19. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
Dassonville O; Bozec A; Fischel JL; Milano G
Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
[TBL] [Abstract][Full Text] [Related]
20. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy.
Morgillo F; Bareschino MA; Bianco R; Tortora G; Ciardiello F
Differentiation; 2007 Nov; 75(9):788-99. PubMed ID: 17608727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
